Retatrutide + Cagrilintide
Also known as: Triple + Amylin Combo, Reta-Cagri
A combination of triple agonist retatrutide with amylin analog cagrilintide for maximum weight loss.
Overview
This combination pairs retatrutide (GLP-1/GIP/glucagon triple agonist) with cagrilintide (amylin analog) for potentially superior weight loss through four complementary pathways. This represents one of the most aggressive peptide approaches to obesity treatment.
Mechanism of Action
Retatrutide: activates GLP-1, GIP, and glucagon receptors for appetite suppression, insulin secretion, and thermogenesis. Cagrilintide: activates amylin receptors for additional appetite suppression and gastric slowing. Four-receptor approach.
Pharmacokinetics
Both are long-acting with weekly dosing. Subcutaneous administration.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Experimental
5mg + 5mg
Once weekly
Variable
Not clinically validated - experimental only
Research Areas
Key Research Findings
- 1Theoretical maximum weight loss combination
- 2Four complementary receptor pathways
- 3Both components show strong individual results
- 4Experimental combination
Side Effects & Contraindications
Reported Side Effects
- Severe nausea likely
- Vomiting
- Diarrhea
- Significant appetite loss
Contraindications
- MTC history
- MEN2
- Severe GI disease
- Gastroparesis
Safety Considerations
Highly experimental combination. Additive GI side effects likely. Not clinically validated as combination. Use extreme caution.
Storage Requirements
Refrigerate 2-8°C
Scientific References
- 1